New Dry Eye Treatment


Dry eye, or what doctors call keratoconjunctivitis sicca, is a fairly widespread problem, affecting an estimated 10 percent to 20 percent of people[1]. But it’s even more common in people with diabetes; research has found that about half of all diabetes patients[2] have dry eye symptoms.

So it comes as good news that the U.S. Food and Drug Administration (FDA) has approved a new treatment for dry eye syndrome[3]. It’s called Cequa, and it’s made by Sun Pharmaceuticals. According to Abhay Gandhi[4], CEO, North America, Sun Pharmaceuticals, “Dry eye disease represents an area of high unmet medical need, with a significant number of patients who are currently untreated. The U.S. FDA approval of Cequa represents a long-awaited dry eye treatment option….”

Cequa is a formulation of cyclosporine A, or CsA. CsA Itself isn’t new; it’s been used to treat dry eye for some 15 years. But Sun Pharmaceuticals says that Cequa is different in two ways. First, it has the highest FDA-approved concentration of CsA (0.09%). Second, it is the first and only FDA-approved CsA product that incorporates what’s known as nanomicellar technology. This technology, Sun says, allows the CsA molecule to “overcome solubility problems” and to penetrate the aqueous layer of the eye. In other words, the tiny size of the nanomicelles makes it easier for high concentrations of CsA to enter the corneal and conjunctival cells.

In its final pre-approval trial, Cequa demonstrated “statistically significant improvement” after 12 weeks of use. Cequa will be sold in a single-use vial and is meant to be applied twice a day.

Want to learn more about diabetes and eye health? Read “Say Goodbye to Dry Eye,”[5] “Keeping Your Eyes Healthy,”[6] and “Avoiding Eye Complications.”[7]

  1. 10 percent to 20 percent of people:
  2. about half of all diabetes patients:
  3. approved a new treatment for dry eye syndrome:
  4. According to Abhay Gandhi:
  5. “Say Goodbye to Dry Eye,”:
  6. “Keeping Your Eyes Healthy,”:
  7. “Avoiding Eye Complications.”:

Source URL:

Joseph Gustaitis: Joseph Gustaitis is a freelance writer and editor based in the Chicago area. (Joseph Gustaitis is not a medical professional.)

Disclaimer of Medical Advice: You understand that the blog posts and comments to such blog posts (whether posted by us, our agents or bloggers, or by users) do not constitute medical advice or recommendation of any kind, and you should not rely on any information contained in such posts or comments to replace consultations with your qualified health care professionals to meet your individual needs. The opinions and other information contained in the blog posts and comments do not reflect the opinions or positions of the Site Proprietor.